Watson Pharmaceuticals Inc has launched Microgestin (norethindrone acetate and ethinyl estradiol tablets), a generic version of the oral contraceptive Loestrin, marketed by Pfizer. Microgestin is indicated for the prevention of pregnancy and will be launched in 1mg /20mcg and 1.5mg /30mcg strengths.

"The launch of Microgestin, paired with our previously launched Microgestin FE, completes our full Microgestin line of oral contraceptives," said Joe Papa, President and Chief Operating Officer. "This launch further supplements our extensive oral contraceptive product portfolio consisting of 14 product families and 22 different product strengths."